Nimbus on cloud 9 as psoriasis data support taking rival to Bristol Myers' Sotyktu...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Nov 30, 2022 at 10:42: AM
via Nimbus Therapeutics is ramping up its pursuit of Bristol Myers Squibb’s plaque psoriasis drug Sotyktu, committing to moving a rival TYK2 inhibitor into phase 3 after hitting the primary endpoint in a midstage study.

article source
 

<



Similar threads

cafead
After two Big Pharma deals, Nimbus looks to keep the hits coming
Replies
0
Views
15
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASCO24: Nimbus Plots Path for Next-Gen IO Therapies with Strong Early HPK1 Blocker Data
Replies
0
Views
92
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
JPM 24: How Takeda beat &#039;almost every biopharmaceutical company&#039; to win Nimbus’...
Replies
0
Views
53
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Fresh off $4B deal, Nimbus gears up for ‘third chapter’ with new fundraise
Replies
0
Views
92
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Nimbus hopes to strike thrice
Replies
0
Views
93
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote